UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
Phase 3
Completed
- Conditions
- IDIOPATHIC PARKINSON'S DISEASE
- Interventions
- Drug: Placebo Patch
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 249
- Registration Number
- NCT01646268
- Locations
- 🇨🇳
001, Beijing, China
🇨🇳002, Beijing, China
🇨🇳019, Beijing, China
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01618903
- Locations
- 🇨🇳
1, Shanghai, China
A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01618877
- Locations
- 🇨🇳
1, Shanghai, China
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)
Terminated
- Conditions
- Rheumatoid ArthritisCrohn's Disease
- First Posted Date
- 2012-04-13
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 199
- Registration Number
- NCT01577264
- Locations
- 🇷🇺
13, Ekaterinburg, Russian Federation
🇷🇺28, Ekaterinburg, Russian Federation
🇷🇺12, Kazan, Russian Federation
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 150
- Registration Number
- NCT01569464
- Locations
- 🇺🇸
006, Birmingham, Alabama, United States
🇺🇸013, Jasper, Alabama, United States
🇺🇸021, Gilbert, Arizona, United States
Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 55
- Registration Number
- NCT01565018
- Locations
- 🇩🇪
1, Neuss, Germany
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01536015
- Locations
- 🇺🇸
011, Birmingham, Alabama, United States
🇺🇸001, Gilbert, Arizona, United States
🇺🇸022, Fountain Valley, California, United States
Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects
Phase 2
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: Epratuzumab
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 17
- Registration Number
- NCT01534403
- Locations
- 🇯🇵
10, Fukuoka, Japan
🇯🇵11, Fukuoka, Japan
🇯🇵9, Fukuoka, Japan
A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01530386
- Locations
- 🇺🇸
005, Little Rock, Arkansas, United States
🇺🇸003, Cleveland, Ohio, United States
🇺🇸004, Austin, Texas, United States
Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT01530022
- Locations
- 🇺🇸
001, Atlanta, Georgia, United States
🇺🇸002, Overland Park, Kansas, United States